A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes
1991; Elsevier BV; Volume: 540; Issue: 1-2 Linguagem: Inglês
10.1016/0006-8993(91)90528-4
ISSN1872-6240
AutoresYehoshua Gozes, Douglas E. Brenneman, Mati Fridkin, Richard Asofsky, Illana Gozes,
Tópico(s)Peptidase Inhibition and Analysis
ResumoVasoactive intestinal peptide (VIP) is a neuropeptide which also interacts with cells of the immune system. The paucity of specific VIP receptor antagonists has hampered studies of possible receptor heterogeneity and of VIP function. To aid in achieving these goals, a new VIP antagonist, a hybrid between neurotensin and VIP, has been synthesized. This peptide interacted with VIP receptors on spinal cord cells with an affinity 10-fold greater than VIP itself. In contrast, 1000-fold higher concentrations of the antagonist were required to displace labeled VIP from its receptor on lymphoid cells as compared to VIP itself, suggesting VIP receptor heterogeneity between immune and spinal cord cells.
Referência(s)